CSBR · Champions Oncology, Inc.

The Board of Directors of Champions Oncology accepted the resignation of Dr. Philip Breitfeld and appointed Dr. Brian Alexander as a director, effective March 24, 2026. Dr. Breitfeld's resignation was not due to any disagreement with the company. Dr. Alexander's appointment is intended to support the company's strategic focus on leveraging clinically relevant data and advanced analytics to enhance its translational oncology research platform. His background includes senior leadership roles at Valo Health, Flagship Pioneering, and Foundation Medicine, with experience in oncology, data science, and drug development. The company stated that no material compensatory arrangements or related party transactions are associated with his appointment. This change aligns with Champions Oncology's stated goal of expanding its data capabilities to inform drug discovery and development more effectively.